** Shares of drugmaker Ultragenyx Pharmaceutical RARE.O rise 2% to $38.75
** JPMorgan raises RARE's target price to $117 from $104
** Believes RARE is uniquely positioned in the long term with a broad and diverse pipeline of orphan disease assets and a highly regarded management team - JPMorgan
** 19 of 20 brokerages rate the stock "buy" or higher, one "hold"; their median PT is $87, according to data compiled by LSEG
** Up to last close, stock had fallen ~10% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。